<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442804</url>
  </required_header>
  <id_info>
    <org_study_id>5150112</org_study_id>
    <nct_id>NCT02442804</nct_id>
  </id_info>
  <brief_title>Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke</brief_title>
  <official_title>The Effects of Pomegranate Polyphenols on Neuropsychological Functioning Following Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pomegranate supplements improve cognitive
      functioning following stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research suggests that antioxidants (substances that may slow or prevent cell damage) found
      in many fruits and vegetables may help improve brain functioning (for example, memory and
      attention) in healthy individuals and prevent cognitive decline in individuals who have
      suffered a stroke. The purpose of this research study is to examine whether dietary
      supplementation with an antioxidant extract can help promote healthy cognitive functioning
      as a component of recovery after stroke. The procedures include: Administering polyphenols
      via 2 POMx pills, each of which contains polyphenols derived from pomegranates equivalent to
      the content of approximately 8 ounces of pomegranate juice, or placebo pills (capsules
      containing no polyphenol ingredients), every day for one week to inpatients who are in the
      acute post-stroke phase. Neuropsychological testing pre- and post-treatment will determine
      whether cognitive functioning changes. Subjects will be randomized into either a placebo or
      polyphenol group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score</measure>
    <time_frame>Baseline and Day 9</time_frame>
    <description>Composite neuropsychological measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Mini-Mental State Examination - 2nd Edition Score</measure>
    <time_frame>Baseline and Day 9</time_frame>
    <description>Neuropsychological screening measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test of Premorbid Functioning (TOPF) Score</measure>
    <time_frame>Day 1</time_frame>
    <description>Neuropsychological measure of estimated intellectual ability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Trail-making Test Score</measure>
    <time_frame>Baseline and Day 9</time_frame>
    <description>Neuropsychological measure of executive functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Brief Test of Attention Score</measure>
    <time_frame>Baseline and Day 9</time_frame>
    <description>Neuropsychological measure of attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Controlled Oral Word Association Test Score</measure>
    <time_frame>Baseline and Day 9</time_frame>
    <description>Neuropsychological measure of verbal fluency</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Stroke - POMx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomegranate supplement (1g) by mouth twice per day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stroke - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>POMx</intervention_name>
    <description>Pomegranate supplement (1g) by mouth twice per day for 7 days</description>
    <arm_group_label>Stroke - POMx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days</description>
    <arm_group_label>Stroke - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suffered an ischemic stroke and admitted to LLUMC Rehabilitation Institute for
             inpatient care

          -  Fluent in English

          -  Between the age of 18 and 89 years old

        Exclusion Criteria:

          -  Less than 6 years of education

          -  Global aphasia

          -  Pregnant

          -  History of allergy to pomegranates

          -  History of traumatic brain injury

          -  Neurodegenerative disease or neurologic condition with known cognitive impact (e.g.,
             Alzheimer's disease)

          -  Active renal disease

          -  Active liver disease

          -  Intracerebral hemorrhage in past 6 months

          -  Neurosurgery in past month

          -  Taking warfarin (Coumadin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Loma Linda University East Campus Hospital</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>25333 Barton Rd</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 9, 2016</lastchanged_date>
  <firstreceived_date>May 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>John Bellone</investigator_full_name>
    <investigator_title>MA</investigator_title>
  </responsible_party>
  <keyword>Pomegranate</keyword>
  <keyword>Stroke</keyword>
  <keyword>Neuropsychology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
